IR News - Page 2 of 2 - Page 2 of 1 - Page 2 of 1

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

 

Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus

 

CHEPLAPHARM has held the rights for…

Read more  /  pdf

2020

CHEPLAPHARM proves its vigour

 

Cheplapharm successfully closes the first project with LEO Pharma

 

This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

Read more  /  pdf

CHEPLAPHARM closes another product portfolio acquisition

 

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

Read more  /  pdf

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Read more  /  pdf

CHEPLAPHARM - Quarterly Update Call Q4 / FY 2019

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019

| Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST

Read more  /  pdf

Corona Virus (COVID-19) Impact on CHEPLAPHARM activities

Due to the COVID-19 situation, CHEPLAPHARM Arzneimittel GmbH is closely monitoring the potential

impact on the various Supply Chains and is committed…

Read more  /  pdf

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,…

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of…

Read more  /  pdf

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

Read more  /  pdf

2019

2018